The first steps towards the era of personalised vaccinology: predicting adverse reactions

Pellegrino, Paolo; Falvella, Felicia Stefania; Perrone, Valentina; Carnovale, Carla; Brusadelli, Tatiana; Pozzi, Marco; Antoniazzi, Stefania; Cheli, Stefania; Perrotta, Cristiana; Clementi, Emilio; Radice, Sonia

doi:10.1038/tpj.2014.57

Cited by 17 publications

(15 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of genetic predisposition in the risk of occurrence of vaccine-related adverse reactions has been discussed largely in recent years [21,50,77,78], with special emphasis on the ''ASIA-Autoimmune/inflammatory Syndrome Induced by Adjuvants'' [79]. The term ''ASIASyndrome'' was coined in 2011 to describe the spectrum of immune-mediated diseases triggered by an adjuvant stimulus [79][80][81][82][83][84][85][86].…”

Section: Discussionmentioning

confidence: 99%

“…A number of studies have been reported on this topic, including significant evidence about the role of several SNPs in cytokines production following vaccinations [44][45][46][47][48][49][50].…”

Section: The Molecular Mechanismmentioning

confidence: 98%

“…As a number of genes and SNPs are known to potentially influence the risk of vaccine-drug interactions by interfering with both immune response [44][45][46][47][48][49][50] and CYP activity [41][42][43], further studies are required to fully explore this topic.…”

Section: The Molecular Mechanismmentioning

confidence: 99%

See 2 more Smart Citations

Vaccine–Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms

et al. 2015

View full text Add to dashboard Cite

Vaccinations are recommended throughout life to reduce the risk of vaccine-preventable diseases and their sequelae. Vaccines are often administered in patients with chronic diseases who are likely to be treated with several drugs. A growing number of clinical observations have indicated the possibility of interactions between vaccines and drugs, leading to changes in drug metabolism after vaccination. These interactions represent a significant concern because of the increasing use of vaccines in older patients who are likely to be treated with several drugs. Because of the possible implications of adverse reactions in terms of public health, several studies were performed to verify the risk posed by these interactions and to clarify the biologic mechanisms that drive these events. Of the several mechanisms proposed to be at the basis of vaccine-drug interactions, the most convincing evidence suggests a role of inflammatory cytokines on the regulation of specific cytochrome P450 enzymes in the liver. Differences in the cytochrome P450 enzymes involved in the metabolism of these drugs could explain these contrasting results and provide important insights to fully understand the clinical importance of these events. Further studies are required to verify whether vaccine-drug interactions may occur in other clinical settings, especially the ones for which patients are required to be vaccinated against specific diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Molecular Mechanismmentioning

confidence: 98%

See 1 more Smart Citation

Vaccine–Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A growing body of literature points to influence of human genetic variability on efficacy as well as tolerability/ adverse effects of a number of vaccines (reviewed in ref. (59,63,71,72)). Specifically, associations of variations in human genes for HLA, cytokines, or cytokine receptors, molecules associated with mounting immune response, have been implicated in determining response to hepatitis B vaccine (73)(74)(75)(76), hepatitis C vaccine (77)(78)(79) as well as a number of childhood vaccines including rubella (80), mumps (81,82), and measles (81)(82)(83), as well as malaria (84).…”

Section: Discussionmentioning

confidence: 99%

“…However, these drugs represent a small fraction of the current and growing list of BTs on the market (10-12). Several technical, logistic, and regulatory factors have been cited as possible barriers (56)(57)(58)(59)(60)(61)(62)(63). Some of these challenges appear to be common both small and large molecule drugs.…”

Section: From Pgx Of Small Molecule Therapeutics To Pgx Of Btsmentioning

confidence: 99%

Recent Advances in Application of Pharmacogenomics for Biotherapeutics

Mahajan

2016

AAPS J

View full text Add to dashboard Cite

Abstract.Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effects, and biocompatible metabolism, in addition to legal and logistic advantages. However, their clinical utility is limited, among other things, by their high immunogenic potential and/or variable therapeutic efficacy in different patient populations. Both of these issues, also commonly experienced with small molecule drugs, have been addressed effectively in a number of cases by the successful application of pharmacogenomic tools and approaches. In this introductory article of the special issue, we review the current state of application of pharmacogenomics to BTs and offer suggestions for further expansion of the field.

show abstract

Prediction of post‐vaccination Guillain‐Barré syndrome using data from a passive surveillance system

Luo

Jiang

et al. 2021

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose Severe adverse events (AEs), such as Guillain‐Barré syndrome (GBS) occur rarely after influenza vaccination. We identify highly associated AEs with GBS and develop prediction models for GBS using the US Vaccine Adverse Event Reporting System (VAERS) reports following trivalent influenza vaccination (FLU3). Methods This study analyzed 80 059 reports from the US VAERS between 1990 and 2017. Several AEs were identified as highly associated with GBS and were used to develop the prediction model. Some common and mild AEs that were suspected to be underreported when GBS occurred simultaneously were removed from the final model. The analyses were validated using European influenza vaccine AEs data from EudraVigilance. Results Of the 80 059 reports, 1185 (1.5%) were annotated as GBS related. Twenty‐four AEs were identified as having strong association with GBS. The full prediction model, using age, sex, and all 24 AEs achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 85.4% (90% CI: [83.8%, 86.9%]). After excluding the nine (e.g., pruritus, rash, injection site pain) likely underreported AEs, the final AUC became 77.5% (90% CI: [75.5%, 79.6%]). Two hundred and one (0.25%) reports were predicted as of high risk of GBS (predicted probability >25%) and 84 actually developed GBS. Conclusion The prediction performance demonstrated the potential of developing risk‐prediction models utilizing the VAERS cohort. Excluding the likely underreported AEs sacrificed some prediction power but made the model more interpretable and feasible. The high absolute risk of even a small number of AE combinations suggests the promise of GBS prediction within the VAERS dataset.

show abstract

The first steps towards the era of personalised vaccinology: predicting adverse reactions

Cited by 17 publications

References 47 publications

Vaccine–Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms

Vaccine–Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms

Recent Advances in Application of Pharmacogenomics for Biotherapeutics

Prediction of post‐vaccination Guillain‐Barré syndrome using data from a passive surveillance system

Contact Info

Product

Resources

About